MediWound Ltd.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ofer Gonen
- Full Time Employees
- 121
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 42 Hayarkon Street Yavne HM Israel 8122745
- IPO Date
- Mar 20, 2014
- CIK
- 0001593984
- Website
- mediwound.com
- Similar Companies
- Business
- MediWound Ltd. (Nasdaq: MDWD) develops, manufactures and commercializes next-generation enzymatic therapeutics for non-surgical tissue repair, focusing on wound and burn care; its lead product, NexoBrid, an FDA-, EMA- and PMDA-approved orphan biologic, removes eschar from deep partial- and full-thickness thermal burns in adults and pediatric patients; its Phase III pipeline candidate, EscharEx, a biological drug, targets debridement of chronic and hard-to-heal wounds such as venous leg ulcers and diabetic foot ulcers. The company operates a fully vertically integrated model with in-house cGMP-certified sterile manufacturing, advanced R&D including in vitro/in vivo models and analytical methods, and global commercialization through strategic partnerships including Vericel Corp. in the U.S., direct sales and PMI promotion in Europe (DACH region), and collaborations in Japan, Australia, India and 45 countries worldwide. Founded in 2000 and headquartered at 42 Hayarkon Street, Yavne, Israel, MediWound serves burn centers, hospitals and wound care settings, treating over 16,000 patients to date with improved outcomes and reduced surgical needs. Recent developments include completion of commissioning for a sixfold expanded NexoBrid manufacturing facility reaching full capacity by year-end 2025; ongoing enrollment in the VALUE Phase III trial for EscharEx in venous leg ulcers with diabetic foot ulcer trial planned for H2 2026; Therapeutic Goods Administration approval of NexoBrid in Australia; $30 million equity financing from healthcare investors; and a strategic $15 million PIPE investment from Mölnlycke Health Care in 2024 with collaboration on R&D and partnerships.
Company News
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MediWound Ltd. (MDWD) Q2 2026 Earnings Call Transcript
MediWound Q2 Earnings Call Highlights
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MediWound to Report Second Quarter 2026 Financial Results
MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript
MediWound Q1 Earnings Call Highlights
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
MediWound to Report First Quarter 2026 Financial Results
Head-To-Head Review: Surrozen (NASDAQ:SRZN) & MediWound (NASDAQ:MDWD)
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
Head-To-Head Analysis: MediWound (NASDAQ:MDWD) & Dyne Therapeutics (NASDAQ:DYN)
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
MediWound Files Annual Report on Form 20-F
MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results